Pegfilgrastim (Neulasta) Supports Dose-Dense Chop-R Given Every 14 Days to Patients With Non-Hodgkin's Lymphoma

2.50
Hdl Handle:
http://hdl.handle.net/10755/164644
Category:
Abstract
Type:
Presentation
Title:
Pegfilgrastim (Neulasta) Supports Dose-Dense Chop-R Given Every 14 Days to Patients With Non-Hodgkin's Lymphoma
Author(s):
Merriman, N.; O'Rourke, E.; Dyer, S.; Moore, T.; Miller, K.
Author Details:
N. Merriman, Oncology/Hematology, Columbus, Ohio, USA; E. O�Rourke; S. Dyer; T. Moore; K. Miller
Abstract:
CHOP has long been the treatment of choice for aggressive NHL. Attempts to improve upon CHOP with more complex or higher dose regimens have resulted in greater toxicity, but not greater efficacy. Maintaining CHOP dose intensity has been associated with improved survival, and it is possible that increasing the dose-intensity by decreasing the time between cycles may further improve outcomes. Recently, investigators have shown that CHOP given every 14 days with Filgrastim support is superior to standard 21-day CHOP (Blood 2001;98:725a). In addition, adding the monoclonal antibody rituximab to standard CHOP (CHOP-R) has also been shown to improve survival (NEJM 2002;346:235). Given these advances, the next logical step is to evaluate dose-dense CHOP-R. This phase II trial was designed to assess the feasibility of giving CHOP-R every 14 days with pegfilgrastim, rather than daily Filgrastim. Pegfilgrastim, a pegylated version of Filgrastim, is administered as a single 6-mg fixed dose just once per chemotherapy cycle. Patients with previously untreated intermediate- or aggressive NHL and relapsed low-grade NHL were eligible for this study. Rituximab was given on day 1, CHOP on day 3, and pegfilgrastim on day 4, for up to 8 cycles. To date, 15 patients have entered the trial (mean age of 61, range 37–77; 8 females, 7 males); 10 have completed therapy and 5 remain in treatment. A total of 84 cycles have been administered. Eight cycles have been delayed for toxicity (grade 2 diarrhea, n=1; grade 3 stomatitis/pharyngitis, n=4; grade 4 thrombocytopenia and neutropenia, n=3) and 4 patients have had an episode of febrile neutropenia. Fully 90% of planned cycles were given on time, with no dose reductions, and all patients have attained a CR or near-CR status with no evidence of progressive disease. Complete data for the protocol-planned 30 enrolled patients will be presented at the meeting. These preliminary results suggest that CHOP-R can be given safely every 14 days with pegfilgrastim support. Oncology nurses may see dose-dense CHOP and CHOP-R increasingly used in practice. Data regarding the effects of pegfilgrastim with these regimens are important, as nurses will be integral in administering this therapy.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2003
Conference Name:
28th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Denver, Colorado, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titlePegfilgrastim (Neulasta) Supports Dose-Dense Chop-R Given Every 14 Days to Patients With Non-Hodgkin's Lymphomaen_GB
dc.contributor.authorMerriman, N.en_US
dc.contributor.authorO'Rourke, E.en_US
dc.contributor.authorDyer, S.en_US
dc.contributor.authorMoore, T.en_US
dc.contributor.authorMiller, K.en_US
dc.author.detailsN. Merriman, Oncology/Hematology, Columbus, Ohio, USA; E. O�Rourke; S. Dyer; T. Moore; K. Milleren_US
dc.identifier.urihttp://hdl.handle.net/10755/164644-
dc.description.abstractCHOP has long been the treatment of choice for aggressive NHL. Attempts to improve upon CHOP with more complex or higher dose regimens have resulted in greater toxicity, but not greater efficacy. Maintaining CHOP dose intensity has been associated with improved survival, and it is possible that increasing the dose-intensity by decreasing the time between cycles may further improve outcomes. Recently, investigators have shown that CHOP given every 14 days with Filgrastim support is superior to standard 21-day CHOP (Blood 2001;98:725a). In addition, adding the monoclonal antibody rituximab to standard CHOP (CHOP-R) has also been shown to improve survival (NEJM 2002;346:235). Given these advances, the next logical step is to evaluate dose-dense CHOP-R. This phase II trial was designed to assess the feasibility of giving CHOP-R every 14 days with pegfilgrastim, rather than daily Filgrastim. Pegfilgrastim, a pegylated version of Filgrastim, is administered as a single 6-mg fixed dose just once per chemotherapy cycle. Patients with previously untreated intermediate- or aggressive NHL and relapsed low-grade NHL were eligible for this study. Rituximab was given on day 1, CHOP on day 3, and pegfilgrastim on day 4, for up to 8 cycles. To date, 15 patients have entered the trial (mean age of 61, range 37–77; 8 females, 7 males); 10 have completed therapy and 5 remain in treatment. A total of 84 cycles have been administered. Eight cycles have been delayed for toxicity (grade 2 diarrhea, n=1; grade 3 stomatitis/pharyngitis, n=4; grade 4 thrombocytopenia and neutropenia, n=3) and 4 patients have had an episode of febrile neutropenia. Fully 90% of planned cycles were given on time, with no dose reductions, and all patients have attained a CR or near-CR status with no evidence of progressive disease. Complete data for the protocol-planned 30 enrolled patients will be presented at the meeting. These preliminary results suggest that CHOP-R can be given safely every 14 days with pegfilgrastim support. Oncology nurses may see dose-dense CHOP and CHOP-R increasingly used in practice. Data regarding the effects of pegfilgrastim with these regimens are important, as nurses will be integral in administering this therapy.en_GB
dc.date.available2011-10-27T12:04:25Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:04:25Z-
dc.conference.date2003en_US
dc.conference.name28th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationDenver, Colorado, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.